A World Without Cervical Cancer: Preventive Medicine publishes special issue to further global efforts to eliminate deadly disease
Recognizing the urgent public health issue concerning Cervical Cancer, the editorial team of Preventive Medicine is publishing a special issue titled “From Science to Action to Impact: Eliminating Cervical Cancer,” which outlines the required courses of action to eliminate cervical cancer featuring Yale's Dr. Linda Niccolai.
A closer look at the impact of COVID-19 on cardio-oncology
In response to the COVID-19 pandemic, Lauren Baldassarre, MD, and members of the Cardio-Oncology and Imaging Councils of the American College of Cardiology shared recommendations regarding the cardiovascular care of COVID-19-positive patients.
New Immunotherapy Treatment for Lung Cancer
More than 200,000 people a year in the United States are diagnosed with non-small cell lung cancers, which make up about 80 percent of all lung cancers. Now, the results of a phase three clinical trial show the immunotherapy drug atezolizumab, also known as Tecentriq, improves survival.Source: ABC News 12
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Yale Doc Says Lowering Recommended Age For Colon Screening is Critical Following Rise in Colorectal Cancer in Younger Patients
The United States Preventative Services taskforce has released a recommendation that colon cancer screenings start at age 45 instead of 50. It’s because more young people are being diagnosed with colon cancer. Dr. Pamela Kunz says the new recommendation is due to the staggering hike in younger cases of colon cancer.Source: WTNH News 8
Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
Humanized Mice Lead to Breakthroughs in Blood Cancers
Humanized mice created at Yale are opening new avenues of research into cancers caused by disorders in the production of blood, such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Until recently, such research was hindered because human blood stem cells are difficult to grow in cell cultures or to engraft in mice.
Dark Chemical Matter and Colon Cancer
Seven years ago, Jason Crawford, PhD, began chasing a ghost: A bacterial toxin named colibactin. He was looking for its molecular structure. He could detect bits of it, but never enough to form an entire likeness. Four years into the hunt he asked Seth Herzon, PhD, to join him. They pursued colibactin so doggedly because it is associated with up to 67 percent of all colon cancers.
The Microbiome and Cancer Treatment
Andrew Goodman, PhD, studies the abundant flora in the gut, but he initially trained in ecology and sees many parallels. He thinks of the microbiome as an ecosystem and the members of the ecosystem as bacteria. His recent research reveals that microbes are dynamic agents that should be considered in medical care.
Cancer and Obesity: The Link is Insulin
Nearly 40 percent of Americans over the age of 20 are obese, and another 32 percent are overweight. These alarming figures grow darker when combined with statistics showing that obesity is second only to smoking as a cause of preventable cancer deaths. Obesity has been linked to more than a dozen types of cancer.
From Paradox to Breakthrough
Aaron Ring, MD, PhD, was hooked by a paradox. He had been studying cytokines to understand their potential to stimulate anti-tumor immunity. Though cytokines, such as interleukin-2, have been in clinical use for decades, they have historically shown only limited effectiveness. Dr. Ring was hunting for interleukins that could deliver a specific signal to activate TILs.
Ten Years of Leadership in Immunotherapy
The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.
Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers'
A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as “drivers” — variations in DNA sequences that lead to the development of cancer.